Drugs / QEL-005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07473154 | Apr 2026 → Aug 2028 expected | diffuse cutaneous systemic sclerosis, rheumatoid arthritis | Quell Therapeutics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-25 | Quell Therapeutics Limited | Results Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025 quell-tx.com ↗
Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and inflammatory macrophages |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-03 | Quell Therapeutics Limited | Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval quell-tx.com ↗ |
| 2025-10-25 | Quell Therapeutics Limited | Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025 quell-tx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QEL-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07473154 ↗ |
| Modality | Cell therapy | “QEL-005 is an autologous cell therapy” NCT07473154 ↗ |
| Route | Intravenous | “given back to the participant by intravenous (IV) infusion” NCT07473154 ↗ |
| Target | CD19 | “target a protein on B cells called CD19” NCT07473154 ↗ |